For nearly 50 years, NAMSA has focused on offering the most critical services required to accelerate time-to-market and reduce costs for medical device research clients across the world. Consistently recognized as a pioneer in medical device development – most recently with the honor of the “CRO Leadership Award,” presented by Life Science Leader magazine – NAMSA has a proven and established track record of delivering expedited results through the utilization of its translational research methods.
Naglreiter, similarly placing a significant concentration on providing efficacious customer outcomes, applies an integrated approach to its design, development and manufacturing service offerings. Providing end-to-end solutions for over 20 years, Naglreiter focuses on technical and design alternatives that reduce costs and fast-track timelines that move clients into device production as quickly as possible.
This partnership, drawing upon a combined 70 years’ experience in assisting thousands of customers to successfully commercialize products throughout the world, will now provide early-stage medical device firms a single source, powerhouse solution through its combined full-service offering.
“We are extremely excited about this unique partnership that will result in more predictable development timelines, increased cost savings and unparalleled time-to-market for device firms,”John Amat, NAMSA’s chief commercial officer.
“Naglreiter’s ‘Product Lifecycle Management’ methodology of innovation perfectly complements NAMSA’s ‘MRO Approach,’” Amat said. “Together, we will be able to more effectively drive start-up device programs and appropriately address the challenges and risks that these organizations face due to fragmented resources and increasingly complicated regulatory landscapes.”
Naglreiter President Brett Naglreiter said, “We fully expect our partnership to provide customers with further efficiencies that result from having access to a comprehensive portfolio of development resources and commercialization services that are managed through a single source.”
NAMSA and Naglereiter look forward to providing early-stage medical device organizations with a unique, world-class solution that will allow them to bring life-changing therapies to the marketplace in the most efficient manner possible.
[Want to stay more on top of MDO content? Subscribe to our weekly e-newsletter.]